Shin Nippon Biomedical's Satsuma gains FDA approval for Atzumi™

Shin Nippon Biomedical Laboratories (SNBL) [TSE:2395] has announced that its U.S. subsidiary, Satsuma Pharmaceuticals, Inc., received FDA approval for Atzumi™ (dihydroergotamine) nasal powder, previously known as STS101, for the acute treatment of migraine. Atzumi™ is the first FDA-approved intranasal drug developed using SNBL's proprietary nasal drug delivery platform technology. The drug combines the long-proven benefits of DHE with a patient-friendly delivery system.